Pandemic H1N1 2009 (‘swine flu’): diagnostic and other challenges

  title={Pandemic H1N1 2009 (‘swine flu’): diagnostic and other challenges},
  author={Hans Joachim Burkardt},
  journal={Expert Review of Molecular Diagnostics},
  pages={35 - 40}
  • H. Burkardt
  • Published 1 January 2011
  • Medicine
  • Expert Review of Molecular Diagnostics
Pandemic H1N1 2009 (‘swine flu’) virus was ‘the virus of the year 2009’ because it affected the lives of many people in this year. H1N1 was first described in California in April 2009 and spread very rapidly all over the globe. The fast global penetration of the swine flu caused the WHO in Geneva to call the infection with H1N1 a new pandemic with a rapid escalation of the different pandemic phases that ended on 11 June 2009, with the declaration of phase 6 (full-blown pandemic). This had far… 
Retrospective Analysis of Early Impact of COVID-19 on Systemic Cancer Treatment—A Pilot Study
During PLRP, active systemic cancer care seems to have been less affected, whereas follow-up of patients and visits of elderly patients were significantly reduced, which shows the importance of flattening the curve for quality management of other diseases during a pandemic.
Implications of protein conformations to modifying novel inhibitor Oseltamivir for 2009 H1N1 influenza A virus by simulation and docking studies
The fragment-based drug development followed by fragment evolution on the basis of protein conformations after every 10 ns of 100 ns simulation shows the concept of conformations and protein–ligand interactions can be useful in designing new drugs for H1N1 with high specific binding.
Knowledge, attitude, and behaviour of public health doctors towards pandemic influenza compared to the general population in Italy
Physicians had a better ability to deal the pandemic, both for knowledge and behaviours, and this needs to be taken into account for future successful communication in cases of emergency.
New cryptotanshinone derivatives with anti-influenza A virus activities obtained via biotransformation by Mucor rouxii
This paper provides an efficient platform to diversify the structure and pharmaceutical potentials of known natural products. Seven metabolites were obtained via the biotransformation of
New butyrolactone derivatives from the endophytic Fungus Talaromyces sp. CPCC 400783 of Reynoutria japonica Houtt.
Six new butyrolactone derivatives (1, 2a/2b, 3a/3b and 4), together with another two known derivatives (5 and 6) were isolated from the endophytic fungus Talaromyces sp. CPCC 400783. Their structures


In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses
It is shown that CA04 is sensitive to approved and experimental antiviral drugs, suggesting that these compounds could function as a first line of defence against the recently declared S-OIV pandemic.
Severe respiratory disease concurrent with the circulation of H1N1 influenza.
There was a sudden increase in the rate of severe pneumonia and a shift in the age distribution of patients with such illness, which was reminiscent of past pandemics and suggested relative protection for persons who were exposed to H1N1 strains during childhood before the 1957 pandemic.
Emergence and pandemic potential of swine-origin H1N1 influenza virus
Efforts to control these outbreaks and real-time monitoring of the evolution of this virus should provide invaluable information to direct infectious disease control programmes and to improve understanding of the factors that determine viral pathogenicity and/or transmissibility.
Drugs in Development for Influenza
It is important that novel anti-influenza drugs with broad reactivity against all strains and subtypes are developed, and the use of multiple drug therapy is considered, as the efficacy of these drugs declines.
Sensitivity of Rapid Influenza Diagnostic Testing for Swine-Origin 2009 A (H1N1) Influenza Virus in Children
The sensitivity of RIDT for detection of S-OIV is higher than recently reported in mixed adult-pediatric populations but remains suboptimal.
Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season.
Overall, the clinical effect of ORVs in Europe, measured by influenza-like illness or acute respiratory infection, was unremarkable and consistent with normal seasonal activity.
Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis--North Carolina, 2009.
Health-care providers should be aware that antiviral resistance can develop during chemoprophylaxis or treatment with subtherapeutic dosages and should follow published recommendations for antiviral medications.
Diagnostic performance of rapid influenza antigen assays in patients infected with the new influenza A (H1N1) virus
Abstract Background: The new swine influenza (H1N1) requires fast and accurate diagnosis. Currently, there are few reports about the diagnostic performance of influenza antigen tests with regard to
Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
The Advisory Committee on Immunization Practices recommends routine vaccination of U.S. infants with 3 doses of this rotavirus vaccine administered orally at ages 2, 4, and 6 months.